676 results on '"Gessani A"'
Search Results
2. Long-term effects of bilateral subthalamic nucleus deep brain stimulation on gait disorders in Parkinson’s disease: a clinical-instrumental study
- Author
-
Cavallieri, Francesco, Campanini, Isabella, Gessani, Annalisa, Budriesi, Carla, Fioravanti, Valentina, Di Rauso, Giulia, Feletti, Alberto, Damiano, Benedetta, Scaltriti, Sara, Guagnano, Noemi, Bardi, Elisa, Corni, Maria Giulia, Rossi, Jessica, Antonelli, Francesca, Cavalleri, Francesca, Molinari, Maria Angela, Contardi, Sara, Menozzi, Elisa, Puzzolante, Annette, Vannozzi, Giuseppe, Bergamini, Elena, Pavesi, Giacomo, Meoni, Sara, Fraix, Valérie, Fraternali, Alessandro, Versari, Annibale, Lusuardi, Mirco, Biagini, Giuseppe, Merlo, Andrea, Moro, Elena, and Valzania, Franco
- Published
- 2023
- Full Text
- View/download PDF
3. Author Correction: Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson’s disease
- Author
-
Gessani, Annalisa, Cavallieri, Francesco, Fioravanti, Valentina, Campanini, Isabella, Merlo, Andrea, Di Rauso, Giulia, Damiano, Benedetta, Scaltriti, Sara, Bardi, Elisa, Corni, Maria Giulia, Antonelli, Francesca, Cavalleri, Francesca, Molinari, Maria Angela, Contardi, Sara, Menozzi, Elisa, Fraternali, Alessandro, Versari, Annibale, Biagini, Giuseppe, Fraix, Valérie, Pinto, Serge, Moro, Elena, Budriesi, Carla, and Valzania, Franco
- Published
- 2023
- Full Text
- View/download PDF
4. Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson’s disease
- Author
-
Gessani, Annalisa, Cavallieri, Francesco, Fioravanti, Valentina, Campanini, Isabella, Merlo, Andrea, Di Rauso, Giulia, Damiano, Benedetta, Scaltriti, Sara, Bardi, Elisa, Corni, Maria Giulia, Antonelli, Francesca, Cavalleri, Francesca, Molinari, Maria Angela, Contardi, Sara, Menozzi, Elisa, Fraternali, Alessandro, Versari, Annibale, Biagini, Giuseppe, Fraix, Valérie, Pinto, Serge, Moro, Elena, Budriesi, Carla, and Valzania, Franco
- Published
- 2023
- Full Text
- View/download PDF
5. Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson’s disease
- Author
-
Annalisa Gessani, Francesco Cavallieri, Valentina Fioravanti, Isabella Campanini, Andrea Merlo, Giulia Di Rauso, Benedetta Damiano, Sara Scaltriti, Elisa Bardi, Maria Giulia Corni, Francesca Antonelli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Alessandro Fraternali, Annibale Versari, Giuseppe Biagini, Valérie Fraix, Serge Pinto, Elena Moro, Carla Budriesi, and Franco Valzania
- Subjects
Medicine ,Science - Abstract
Abstract Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment in advanced Parkinson’s Disease (PD). However, the effects of STN-DBS on speech are still debated, particularly in the long-term follow-up. The objective of this study was to evaluate the long-term effects of bilateral STN-DBS on speech in a cohort of advanced PD patients treated with bilateral STN-DBS. Each patient was assessed before surgery through a neurological evaluation and a perceptual-acoustic analysis of speech and re-assessed in the long-term in different stimulation and drug conditions. The primary outcome was the percentage change of speech intelligibility obtained by comparing the postoperative on-stimulation/off-medication condition with the preoperative off-medication condition. Twenty-five PD patients treated with bilateral STN-DBS with a 5-year follow-up were included. In the long-term, speech intelligibility stayed at the same level as preoperative values when compared with preoperative values. STN-DBS induced a significant acute improvement of speech intelligibility (p
- Published
- 2023
- Full Text
- View/download PDF
6. Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort studyResearch in context
- Author
-
Elisabetta Zucchi, Umberto Maria Musazzi, Guido Fedele, Ilaria Martinelli, Giulia Gianferrari, Cecilia Simonini, Nicola Fini, Andrea Ghezzi, Maria Caputo, Elisabetta Sette, Veria Vacchiano, Lucia Zinno, Pietro Anceschi, Elena Canali, Marco Vinceti, Salvatore Ferro, Jessica Mandrioli, Laura Ferri, Annalisa Gessani, Rocco Liguori, Pietro Cortelli, Roberto Michelucci, Fabrizio Salvi, Ilaria Bartolomei, Anna Maria Borghi, Andrea Zini, Rita Rinaldi, Valeria Tugnoli, Maura Pugliatti, Luca Codeluppi, Franco Valzania, Filippo Stragliati, Andi Nuredini, Sonia Romano, Alessandro D'Orsi, Liborio Parrino, Doriana Medici, Giovanna Pilurzi, Emilio Terlizzi, Donata Guidetti, Silvia De Pasqua, Mario Santangelo, Paola De Massis, Matteo Gizzi, Mario Casmiro, Pietro Querzani, Simonetta Morresi, Maria Vitiello, Marco Longoni, Alberto Patuelli, Susanna Malagù, Francesca Bianchi, Marco Currò Dossi, and Cristiana Ganino
- Subjects
Amyotrophic lateral sclerosis ,Tauroursodeoxycholic acid ,Real-world evidence ,Propensity score matching ,Survival ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Oral tauroursodeoxycholic acid (TUDCA) is a commercial drug currently tested in patients with amyotrophic lateral sclerosis (ALS) both singly and combined with sodium phenylbutyrate. This retrospective study aimed to investigate, in a real-world setting, whether TUDCA had an impact on the overall survival of patients with ALS who were treated with this drug compared to those patients who received standard care only. Methods: This propensity score–matched study was conducted in the Emilia Romagna Region (Italy), which has had an ALS regional registry since 2009. Out of 627 patients with ALS diagnosed from January 1st, 2015 to June 30th, 2021 and recorded in the registry with available information on death/tracheostomy, 86 patients took TUDCA and were matched in a 1:2 ratio with patients who received only usual care according to age at onset, sex, phenotype, diagnostic latency, ALS Functional Rating Scale-Revised (ALSFRS-R) at first visit, disease progression rate at first visit, and BMI at diagnosis. The primary outcome was survival difference (time from onset of symptoms to tracheostomy/death) between TUDCA exposed and unexposed patients. Findings: A total of 86 patients treated with TUDCA were matched to 172 patients who did not receive treatment. TUDCA-exposed patients were stratified based on dosage (less than or equal to 1000 mg/day or greater) and duration (less than or equal to 12 months or longer) of treatment. The median overall survival was 49.6 months (95% CI 41.7–93.5) among those treated with TUDCA and 36.2 months (95% CI 32.7–41.6) in the control group, with a reduced risk of death observed in patients exposed to a higher dosage (defined as ≥ 1000 mg/day) of TUDCA (HR 0.56; 95% CI 0.38–0.83; p = 0.0042) compared to both the control group and those with lower TUDCA dosages (defined as
- Published
- 2023
- Full Text
- View/download PDF
7. Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study
- Author
-
Ferri, Laura, Gessani, Annalisa, Liguori, Rocco, Cortelli, Pietro, Michelucci, Roberto, Salvi, Fabrizio, Bartolomei, Ilaria, Borghi, Anna Maria, Zini, Andrea, Rinaldi, Rita, Tugnoli, Valeria, Pugliatti, Maura, Codeluppi, Luca, Valzania, Franco, Stragliati, Filippo, Nuredini, Andi, Romano, Sonia, D'Orsi, Alessandro, Parrino, Liborio, Medici, Doriana, Pilurzi, Giovanna, Terlizzi, Emilio, Guidetti, Donata, De Pasqua, Silvia, Santangelo, Mario, De Massis, Paola, Gizzi, Matteo, Casmiro, Mario, Querzani, Pietro, Morresi, Simonetta, Vitiello, Maria, Longoni, Marco, Patuelli, Alberto, Malagù, Susanna, Bianchi, Francesca, Dossi, Marco Currò, Ganino, Cristiana, Zucchi, Elisabetta, Musazzi, Umberto Maria, Fedele, Guido, Martinelli, Ilaria, Gianferrari, Giulia, Simonini, Cecilia, Fini, Nicola, Ghezzi, Andrea, Caputo, Maria, Sette, Elisabetta, Vacchiano, Veria, Zinno, Lucia, Anceschi, Pietro, Canali, Elena, Vinceti, Marco, Ferro, Salvatore, and Mandrioli, Jessica
- Published
- 2023
- Full Text
- View/download PDF
8. Gene and lncRNA Profiling of ω3/ω6 Polyunsaturated Fatty Acid-Exposed Human Visceral Adipocytes Uncovers Different Responses in Healthy Lean, Obese and Colorectal Cancer-Affected Individuals
- Author
-
Sabrina Tait, Enrica Calura, Antonella Baldassarre, Andrea Masotti, Barbara Varano, Sandra Gessani, Lucia Conti, and Manuela Del Cornò
- Subjects
polyunsaturated fatty acids ,adipose tissue ,obesity ,colorectal cancer ,long non-coding RNA ,transcriptome ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Colorectal cancer (CRC) is a major life-threatening disease, being the third most common cancer and a leading cause of death worldwide. Enhanced adiposity, particularly visceral fat, is a major risk factor for CRC, and obesity-associated alterations in metabolic, inflammatory and immune profiles in visceral adipose tissue (VAT) strongly contribute to promoting or sustaining intestinal carcinogenesis. The role of diet and nutrition in obesity and CRC has been extensively demonstrated, and AT represents the main place where diet-induced signals are integrated. Among the factors introduced with diet and processed or enriched in AT, ω3/ω6 polyunsaturated fatty acids (PUFAs) are endowed with pro- or anti-inflammatory properties and have been shown to exert either promoting or protective roles in CRC. In this study, we investigated the impact of ex vivo exposure to the ω3 and ω6 PUFAs docosahexaenoic and arachidonic acids on VAT adipocyte whole transcription in healthy lean, obese and CRC-affected individuals. High-throughput sequencing of protein-coding and long non-coding RNAs allowed us to identify specific pathways and regulatory circuits controlled by PUFAs and highlighted an impaired responsiveness of obese and CRC-affected individuals as compared to the strong response observed in healthy lean subjects. This further supports the role of healthy diets and balanced ω3/ω6 PUFA intake in the primary prevention of obesity and cancer.
- Published
- 2024
- Full Text
- View/download PDF
9. A study on the correlations between acoustic speech variables and bradykinesia in advanced Parkinson's disease
- Author
-
Francesco Cavallieri, Giulia Di Rauso, Annalisa Gessani, Carla Budriesi, Valentina Fioravanti, Sara Contardi, Elisa Menozzi, Serge Pinto, Elena Moro, Francesca Antonelli, and Franco Valzania
- Subjects
acoustic ,bradykinesia ,dysarthria ,Parkinson's disease ,speech ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
BackgroundVery few studies have assessed the presence of a possible correlation between speech variables and limb bradykinesia in patients with Parkinson's disease (PD). The objective of this study was to find correlations between different speech variables and upper extremity bradykinesia under different medication conditions in advanced PD patients.MethodsRetrospective data were collected from a cohort of advanced PD patients before and after an acute levodopa challenge. Each patient was assessed with a perceptual-acoustic analysis of speech, which included several quantitative parameters [i.e., maximum phonation time (MPT) and intensity (dB)]; the Unified Parkinson's Disease Rating Scale (UPDRS) (total scores, subscores, and items); and a timed test (a tapping test for 20 s) to quantify upper extremity bradykinesia. Pearson's correlation coefficient was applied to find correlations between the different speech variables and the tapping rate.ResultsA total of 53 PD patients [men: 34; disease duration: 10.66 (SD 4.37) years; age at PD onset: 49.81 years (SD 6.12)] were included. Levodopa intake increased the MPT of sustained phonation (p < 0.01), but it reduced the speech rate (p = 0.05). In the defined-OFF condition, MPT of sustained phonation positively correlated with both bilateral mean (p = 0.044, r-value:0.299) and left (p = 0.033, r-value:0.314) tapping. In the defined-ON condition, the MPT correlated positively with bilateral mean tapping (p = 0.003), left tapping (p = 0.003), and right tapping (p = 0.008).ConclusionThis study confirms the presence of correlations between speech acoustic variables and upper extremity bradykinesia in advanced PD patients. These findings suggest common pathophysiological mechanisms.
- Published
- 2023
- Full Text
- View/download PDF
10. Speech, Gait, and Vestibular Function in Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome
- Author
-
Giulia Di Rauso, Andrea Castellucci, Francesco Cavallieri, Andrea Tozzi, Valentina Fioravanti, Edoardo Monfrini, Annalisa Gessani, Jessica Rossi, Isabella Campanini, Andrea Merlo, Dario Ronchi, Manuela Napoli, Rosario Pascarella, Sara Grisanti, Giuseppe Ferrulli, Rossella Sabadini, Alessio Di Fonzo, Angelo Ghidini, and Franco Valzania
- Subjects
ataxia ,balance ,CANVAS ,dysarthria ,gait ,RFC1 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
(1) Background: Cerebellar ataxia with neuropathy and vestibular areflexia syndrome (CANVAS) is characterized by late-onset cerebellar ataxia, bilateral vestibulopathy, and sensory neuronopathy mostly due to biallelic RFC1 expansion. (2) Objectives: The aim of this case series is to describe vestibular, gait, and speech alterations in CANVAS via a systematic approach. (3) Methods: All patients (n = 5) underwent a standardized clinical–instrumental examination, including the perceptual and acoustic analysis of speech, instrumental gait, and balance analysis (posturographic data were acquired using a force plate [Kistler, Winterthur, Switzerland] while 3D gait analysis, inclusive of surface electromyography, was acquired using a motion capture system [SMART DX, BTS Bioengineering, Milan, Italy], a wireless electromyograph [FreeEMG, BTS Bioengineering, Milan, Italy]), and vestibular assessment with video-oculography. (4) Results: Five patients were included in the analysis: three females (patients A, B, C) and two males (patients D and E) with a mean age at evaluation of 62 years (SD ± 15.16, range 36–74). The mean age of symptoms’ onset was 55.6 years (SD ± 15.04, range 30–68), and patients were clinically and instrumentally evaluated with a mean disease duration of 6.4 years (SD ± 0.54, range 6–7). Video-Frenzel examination documented spontaneous downbeat nystagmus enhanced on bilateral gaze in all patients, except for one presenting with slight downbeat nystagmus in the supine position. All patients exhibited different degrees of symmetrically reduced VOR gain for allsix semicircular canals on the video-head impulse test and an unexpectedly normal (“false negative”) VOR suppression, consistent with combined cerebellar dysfunction and bilateral vestibular loss. Posturographic indices were outside their age-matched normative ranges in all patients, while 3D gait analysis highlighted a reduction in ankle dorsiflexion (limited forward rotation of the tibia over the stance foot during the stance phase of gait and fatigue of the dorsiflexor muscles) and variable out-of-phase activity of plantar flexors during the swing phase. Finally, perceptual-acoustic evaluation of speech showed ataxic dysarthria in three patients. Dysdiadochokinesis, rhythm instability, and irregularity were observed in the oral diadochokinesis task. (5) Conclusions: CANVAS is a recently discovered syndrome that is gaining more and more relevance within late-onset ataxias. In this paper, we aimed to contribute to a detailed description of its phenotype.
- Published
- 2023
- Full Text
- View/download PDF
11. Author Correction: Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson’s disease
- Author
-
Annalisa Gessani, Francesco Cavallieri, Valentina Fioravanti, Isabella Campanini, Andrea Merlo, Giulia Di Rauso, Benedetta Damiano, Sara Scaltriti, Elisa Bardi, Maria Giulia Corni, Francesca Antonelli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Alessandro Fraternali, Annibale Versari, Giuseppe Biagini, Valérie Fraix, Serge Pinto, Elena Moro, Carla Budriesi, and Franco Valzania
- Subjects
Medicine ,Science - Published
- 2023
- Full Text
- View/download PDF
12. Gene and lncRNA Profiling of ω3/ω6 Polyunsaturated Fatty Acid-Exposed Human Visceral Adipocytes Uncovers Different Responses in Healthy Lean, Obese and Colorectal Cancer-Affected Individuals
- Author
-
Tait, Sabrina, primary, Calura, Enrica, additional, Baldassarre, Antonella, additional, Masotti, Andrea, additional, Varano, Barbara, additional, Gessani, Sandra, additional, Conti, Lucia, additional, and Del Cornò, Manuela, additional
- Published
- 2024
- Full Text
- View/download PDF
13. Vestibular Hypofunction in ARSACS Syndrome
- Author
-
Argenziano, Giacomo, primary, Cavallieri, Francesco, additional, Castellucci, Andrea, additional, Fioravanti, Valentina, additional, Di Rauso, Giulia, additional, Gessani, Annalisa, additional, Campanini, Isabella, additional, Merlo, Andrea, additional, Napoli, Manuela, additional, Grisanti, Sara, additional, Rossi, Jessica, additional, Toschi, Giulia, additional, Zini, Chiara, additional, Ghidini, Angelo, additional, and Valzania, Franco, additional
- Published
- 2024
- Full Text
- View/download PDF
14. A case of 18p chromosomal deletion encompassing GNAL in a patient with dystonia-parkinsonism
- Author
-
Rauso, Giulia Di, primary, Cavallieri, Francesco, additional, Monfrini, Edoardo, additional, Fraternali, Alessandro, additional, Fioravanti, Valentina, additional, Grisanti, Sara, additional, Gessani, Annalisa, additional, Campanini, Isabella, additional, Merlo, Andrea, additional, Toschi, Giulia, additional, Napoli, Manuela, additional, Pascarella, Rosario, additional, Silipigni, Rosamaria, additional, Finelli, Palma, additional, Paul, Jefri J, additional, Bauer, Peter, additional, Versari, Annibale, additional, Fonzo, Alessio Di, additional, and Valzania, Franco, additional
- Published
- 2024
- Full Text
- View/download PDF
15. Insight into Elderly ALS Patients in the Emilia Romagna Region: Epidemiological and Clinical Features of Late-Onset ALS in a Prospective, Population-Based Study
- Author
-
Giulia Gianferrari, Ilaria Martinelli, Cecilia Simonini, Elisabetta Zucchi, Nicola Fini, Maria Caputo, Andrea Ghezzi, Annalisa Gessani, Elena Canali, Mario Casmiro, Patrizia De Massis, Marco Curro’ Dossi, Silvia De Pasqua, Rocco Liguori, Marco Longoni, Doriana Medici, Simonetta Morresi, Alberto Patuelli, Maura Pugliatti, Mario Santangelo, Elisabetta Sette, Filippo Stragliati, Emilio Terlizzi, Veria Vacchiano, Lucia Zinno, Salvatore Ferro, Amedeo Amedei, Tommaso Filippini, Marco Vinceti, ERRALS GROUP, and Jessica Mandrioli
- Subjects
amyotrophic lateral sclerosis ,elderly ALS ,epidemiology ,phenotype ,prognosis ,survival ,Science - Abstract
Few studies have focused on elderly (>80 years) amyotrophic lateral sclerosis (ALS) patients, who represent a fragile subgroup generally not included in clinical trials and often neglected because they are more difficult to diagnose and manage. We analyzed the clinical and genetic features of very late-onset ALS patients through a prospective, population-based study in the Emilia Romagna Region of Italy. From 2009 to 2019, 222 (13.76%) out of 1613 patients in incident cases were over 80 years old at diagnosis, with a female predominance (F:M = 1.18). Elderly ALS patients represented 12.02% of patients before 2015 and 15.91% from 2015 onwards (p = 0.024). This group presented with bulbar onset in 38.29% of cases and had worse clinical conditions at diagnosis compared to younger patients, with a lower average BMI (23.12 vs. 24.57 Kg/m2), a higher progression rate (1.43 vs. 0.95 points/month), and a shorter length of survival (a median of 20.77 vs. 36 months). For this subgroup, genetic analyses have seldom been carried out (25% vs. 39.11%) and are generally negative. Finally, elderly patients underwent less frequent nutritional- and respiratory-supporting procedures, and multidisciplinary teams were less involved at follow-up, except for specialist palliative care. The genotypic and phenotypic features of elderly ALS patients could help identify the different environmental and genetic risk factors that determine the age at which disease onset occurs. Since multidisciplinary management can improve a patient’s prognosis, it should be more extensively applied to this fragile group of patients.
- Published
- 2023
- Full Text
- View/download PDF
16. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
- Author
-
Aricò, Eleonora, Bracci, Laura, Castiello, Luciano, Gessani, Sandra, and Belardelli, Filippo
- Published
- 2020
- Full Text
- View/download PDF
17. Revisiting the impact of lifestyle on colorectal cancer risk in a gender perspective
- Author
-
Conti, Lucia, Del Cornò, Manuela, and Gessani, Sandra
- Published
- 2020
- Full Text
- View/download PDF
18. Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study
- Author
-
Zucchi, Elisabetta, primary, Musazzi, Umberto Maria, additional, Fedele, Guido, additional, Martinelli, Ilaria, additional, Gianferrari, Giulia, additional, Simonini, Cecilia, additional, Fini, Nicola, additional, Ghezzi, Andrea, additional, Caputo, Maria, additional, Sette, Elisabetta, additional, Vacchiano, Veria, additional, Zinno, Lucia, additional, Anceschi, Pietro, additional, Canali, Elena, additional, Vinceti, Marco, additional, Ferro, Salvatore, additional, Mandrioli, Jessica, additional, Ferri, Laura, additional, Gessani, Annalisa, additional, Liguori, Rocco, additional, Cortelli, Pietro, additional, Michelucci, Roberto, additional, Salvi, Fabrizio, additional, Bartolomei, Ilaria, additional, Borghi, Anna Maria, additional, Zini, Andrea, additional, Rinaldi, Rita, additional, Tugnoli, Valeria, additional, Pugliatti, Maura, additional, Codeluppi, Luca, additional, Valzania, Franco, additional, Stragliati, Filippo, additional, Nuredini, Andi, additional, Romano, Sonia, additional, D'Orsi, Alessandro, additional, Parrino, Liborio, additional, Medici, Doriana, additional, Pilurzi, Giovanna, additional, Terlizzi, Emilio, additional, Guidetti, Donata, additional, De Pasqua, Silvia, additional, Santangelo, Mario, additional, De Massis, Paola, additional, Gizzi, Matteo, additional, Casmiro, Mario, additional, Querzani, Pietro, additional, Morresi, Simonetta, additional, Vitiello, Maria, additional, Longoni, Marco, additional, Patuelli, Alberto, additional, Malagù, Susanna, additional, Bianchi, Francesca, additional, Dossi, Marco Currò, additional, and Ganino, Cristiana, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Speech, Gait, and Vestibular Function in Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome
- Author
-
Di Rauso, Giulia, primary, Castellucci, Andrea, additional, Cavallieri, Francesco, additional, Tozzi, Andrea, additional, Fioravanti, Valentina, additional, Monfrini, Edoardo, additional, Gessani, Annalisa, additional, Rossi, Jessica, additional, Campanini, Isabella, additional, Merlo, Andrea, additional, Ronchi, Dario, additional, Napoli, Manuela, additional, Pascarella, Rosario, additional, Grisanti, Sara, additional, Ferrulli, Giuseppe, additional, Sabadini, Rossella, additional, Di Fonzo, Alessio, additional, Ghidini, Angelo, additional, and Valzania, Franco, additional
- Published
- 2023
- Full Text
- View/download PDF
20. Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation
- Author
-
Sabbatucci, Michela, Covino, Daniela Angela, Purificato, Cristina, Mallano, Alessandra, Federico, Maurizio, Lu, Jing, Rinaldi, Arturo Ottavio, Pellegrini, Matteo, Bona, Roberta, Michelini, Zuleika, Cara, Andrea, Vella, Stefano, Gessani, Sandra, Andreotti, Mauro, and Fantuzzi, Laura
- Subjects
Microbiology ,Biological Sciences ,Infectious Diseases ,HIV/AIDS ,Genetics ,2.2 Factors relating to the physical environment ,2.1 Biological and endogenous factors ,Aetiology ,Infection ,Cells ,Cultured ,Chemokine CCL2 ,Cytidine Deaminase ,DNA ,Viral ,Gene Expression ,Gene Expression Profiling ,HIV-1 ,Humans ,Macrophages ,Monomeric GTP-Binding Proteins ,Proteins ,SAM Domain and HD Domain-Containing Protein 1 ,Virus Internalization ,Virus Replication ,Monocyte-derived macrophage ,CCL2 ,Restriction ,SAMHD1 ,APOBEC3A ,Clinical Sciences ,Virology - Abstract
BackgroundMacrophages are key targets of HIV-1 infection. We have previously described that the expression of CC chemokine ligand 2 (CCL2) increases during monocyte differentiation to macrophages and it is further up-modulated by HIV-1 exposure. Moreover, CCL2 acts as an autocrine factor that promotes viral replication in infected macrophages. In this study, we dissected the molecular mechanisms by which CCL2 neutralization inhibits HIV-1 replication in monocyte-derived macrophages (MDM), and the potential involvement of the innate restriction factors protein sterile alpha motif (SAM) histidine/aspartic acid (HD) domain containing 1 (SAMHD1) and apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3 (APOBEC3) family members.ResultsCCL2 neutralization potently reduced the number of p24 Gag+ cells during the course of either productive or single cycle infection with HIV-1. In contrast, CCL2 blocking did not modify entry of HIV-1 based Virus Like Particles, thus demonstrating that the restriction involves post-entry steps of the viral life cycle. Notably, the accumulation of viral DNA, both total, integrated and 2-LTR circles, was strongly impaired by neutralization of CCL2. Looking for correlates of HIV-1 DNA accumulation inhibition, we found that the antiviral effect of CCL2 neutralization was independent of the modulation of SAMHD1 expression or function. Conversely, a strong and selective induction of APOBEC3A expression, to levels comparable to those of freshly isolated monocytes, was associated with the inhibition of HIV-1 replication mediated by CCL2 blocking. Interestingly, the CCL2 neutralization mediated increase of APOBEC3A expression was type I IFN independent. Moreover, the transcriptome analysis of the effect of CCL2 blocking on global gene expression revealed that the neutralization of this chemokine resulted in the upmodulation of additional genes involved in the defence response to viruses.ConclusionsNeutralization of endogenous CCL2 determines a profound restriction of HIV-1 replication in primary MDM affecting post-entry steps of the viral life cycle with a mechanism independent of SAMHD1. In addition, CCL2 blocking is associated with induction of APOBEC3A expression, thus unravelling a novel mechanism which might contribute to regulate the expression of innate intracellular viral antagonists in vivo. Thus, our study may potentially lead to the development of new therapeutic strategies for enhancing innate cellular defences against HIV-1 and protecting macrophages from infection.
- Published
- 2015
21. Highlights on the Role of Galectin-3 in Colorectal Cancer and the Preventive/Therapeutic Potential of Food-Derived Inhibitors
- Author
-
Anna Aureli, Manuela Del Cornò, Beatrice Marziani, Sandra Gessani, and Lucia Conti
- Subjects
galectin-3 ,colorectal cancer ,tumor microenvironment ,immunosuppression ,intestinal inflammation ,bioactive food compounds ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Colorectal cancer (CRC) is a leading cause of death worldwide. Despite advances in surgical and therapeutic management, tumor metastases and resistance to therapy still represent major hurdles. CRC risk is highly modifiable by lifestyle factors, including diet, which strongly influences both cancer incidence and related mortality. Galectin-3 (Gal-3) is a multifaceted protein involved in multiple pathophysiological pathways underlying chronic inflammation and cancer. Its versatility is given by the ability to participate in a wide range of tumor-promoting processes, including cell–cell/cell–matrix interactions, cell growth regulation and apoptosis, and the immunosuppressive tumor microenvironment. This review provides an updated summary of preclinical and observational human studies investigating the pathogenetic role of Gal-3 in intestinal inflammation and CRC, as well as the potential of Gal-3 activity inhibition by plant-source food-derived bioactive compounds to control CRC onset/growth. These studies highlight both direct and immuno-mediated effects of Gal-3 on tumor growth and invasiveness and its potential role as a CRC prognostic biomarker. Substantial evidence indicates natural food-derived Gal-3 inhibitors as promising candidates for CRC prevention and therapy. However, critical issues, such as their bioavailability and efficacy, in controlled human studies need to be addressed to translate research progress into clinical applications.
- Published
- 2022
- Full Text
- View/download PDF
22. Dietary habits affect fatty acid composition of visceral adipose tissue in subjects with colorectal cancer or obesity
- Author
-
Scazzocchio, B., Varì, R., Silenzi, A., Giammarioli, S., Masotti, A., Baldassarre, A., Santangelo, C., D’Archivio, M., Giovannini, C., Del Cornò, M., Conti, L., Gessani, S., and Masella, R.
- Published
- 2020
- Full Text
- View/download PDF
23. Freezing of Gait in Parkinson’s Disease Patients Treated with Bilateral Subthalamic Nucleus Deep Brain Stimulation: A Long-Term Overview
- Author
-
Giulia Di Rauso, Francesco Cavallieri, Isabella Campanini, Annalisa Gessani, Valentina Fioravanti, Alberto Feletti, Benedetta Damiano, Sara Scaltriti, Elisa Bardi, Maria Giulia Corni, Francesca Antonelli, Vittorio Rispoli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Annette Puzzolante, Jessica Rossi, Stefano Meletti, Giuseppe Biagini, Giacomo Pavesi, Valerie Fraix, Mirco Lusuardi, Alessandro Fraternali, Annibale Versari, Carla Budriesi, Elena Moro, Andrea Merlo, and Franco Valzania
- Subjects
axial symptoms ,deep brain stimulation ,freezing ,gait ,long-term ,Parkinson’s disease ,Biology (General) ,QH301-705.5 - Abstract
Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment in advanced Parkinson’s Disease (PD). However, the effects of STN-DBS on freezing of gait (FOG) are still debated, particularly in the long-term follow-up (≥5-years). The main aim of the current study is to evaluate the long-term effects of STN-DBS on FOG. Twenty STN-DBS treated PD patients were included. Each patient was assessed before surgery through a detailed neurological evaluation, including FOG score, and revaluated in the long-term (median follow-up: 5-years) in different stimulation and drug conditions. In the long term follow-up, FOG score significantly worsened in the off-stimulation/off-medication condition compared with the pre-operative off-medication assessment (z = −1.930; p = 0.05) but not in the on-stimulation/off-medication (z = −0.357; p = 0.721). There was also a significant improvement of FOG at long-term assessment by comparing on-stimulation/off-medication and off-stimulation/off-medication conditions (z = −2.944; p = 0.003). These results highlight the possible beneficial long-term effects of STN-DBS on FOG.
- Published
- 2022
- Full Text
- View/download PDF
24. A study on the correlations between acoustic speech variables and bradykinesia in advanced Parkinson's disease
- Author
-
Cavallieri, Francesco, primary, Di Rauso, Giulia, additional, Gessani, Annalisa, additional, Budriesi, Carla, additional, Fioravanti, Valentina, additional, Contardi, Sara, additional, Menozzi, Elisa, additional, Pinto, Serge, additional, Moro, Elena, additional, Antonelli, Francesca, additional, and Valzania, Franco, additional
- Published
- 2023
- Full Text
- View/download PDF
25. High‐frequency motor rehabilitation in amyotrophic lateral sclerosis: a randomized clinical trial
- Author
-
Elisabetta Zucchi, Marco Vinceti, Carlotta Malagoli, Nicola Fini, Annalisa Gessani, Antonio Fasano, Romana Rizzi, Elisabetta Sette, Stefano Cavazza, Alena Fiocchi, Sergio Buja, Tiziana Faccioli, Simone Storani, and Jessica Mandrioli
- Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Objective Exercise may be physically and psychologically important for people with ALS, especially in the earlier stages of the disease, and, as a consequence, current ALS clinical management includes individualized rehabilitation as part of multidisciplinary care because. However, while recent studies focused on which type of exercise is more indicated to ALS patients, there is no evidence at which frequency training sessions should be performed. Methods We performed an assessor blinded randomized clinical trial to investigate the superiority of two different frequencies of exercise on rate of progression in ALS. We enrolled 65 patients in two groups: intensive exercise regimen (IER, five sessions/week) versus usual exercise regimen (UER, two sessions/week). The primary aim was to assess if IER decreased disease progression, measured through Amyotrophic Lateral Sclerosis Functional Rating Scale‐Revised, with respect to UER. Secondary aims included assessment of adverse events, tracheostomy‐free survival, motor and respiratory functions, fatigue, quality of life and caregiver burden. Treatment regimen consisted for both groups of the same kind of exercise including aerobic training, endurance training, stretching or assisted active mobilization, differing for frequency of intervention. Results No significant changes in disease progression were found in patients under IER versus UER. At the end of the study, there were no significant differences between the two groups in survival, respiratory function, time to supporting procedures, and quality of life. Adverse events, fatigue, and caregiver burden were not different between the two treatment regimens. Conclusions Despite some limitations, our trial demonstrated that high‐frequency physical exercise was not superior to UER on ALSFRS‐R scores, motor and respiratory functions, survival, fatigue, and quality of life of ALS patients.
- Published
- 2019
- Full Text
- View/download PDF
26. Dopaminergic Treatment Effects on Dysarthric Speech: Acoustic Analysis in a Cohort of Patients With Advanced Parkinson's Disease
- Author
-
Francesco Cavallieri, Carla Budriesi, Annalisa Gessani, Sara Contardi, Valentina Fioravanti, Elisa Menozzi, Serge Pinto, Elena Moro, Franco Valzania, and Francesca Antonelli
- Subjects
acoustic analysis ,dysarthria ,dyskinesias ,levodopa ,Parkinson's disease ,speech ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Importance: The effects of dopaminergic treatment on speech in patients with Parkinson's disease (PD) are often mixed and unclear. The aim of this study was to better elucidate those discrepancies.Methods: Full retrospective data from advanced PD patients before and after an acute levodopa challenge were collected. Acoustic analysis of spontaneous monologue and sustained phonation including several quantitative parameters [i.e., maximum phonation time (MPT); shimmer local dB] as well as the Unified Parkinson's Disease Rating Scale (UPDRS) (total scores, subscores, and items) and the Clinical Dyskinesia Rating Scale (CDRS) were performed in both the defined-OFF and -ON conditions. The primary outcome was the changes of speech parameters after levodopa intake. Secondary outcomes included the analysis of possible correlations of motor features and levodopa-induced dyskinesia (LID) with acoustic speech parameters. Statistical analysis included paired t-test between the ON and OFF data (calculated separately for male and female subgroups) and Pearson correlation between speech and motor data.Results: In 50 PD patients (male: 32; female: 18), levodopa significantly increased the MPT of sustained phonation in female patients (p < 0.01). In the OFF-state, the UPDRS part-III speech item negatively correlated with MPT (p = 0.02), whereas in the ON-state, it correlated positively with the shimmer local dB (p = 0.01), an expression of poorer voice quality. The total CDRS score and axial subscores strongly correlated with the ON-state shimmer local dB (p = 0.01 and p < 0.01, respectively).Conclusions: Our findings emphasize that levodopa has a poor effect on speech acoustic parameters. The intensity and location of LID negatively influenced speech quality.
- Published
- 2021
- Full Text
- View/download PDF
27. Epidemiological, Clinical and Genetic Features of ALS in the Last Decade: A Prospective Population-Based Study in the Emilia Romagna Region of Italy
- Author
-
Giulia Gianferrari, Ilaria Martinelli, Elisabetta Zucchi, Cecilia Simonini, Nicola Fini, Marco Vinceti, Salvatore Ferro, Annalisa Gessani, Elena Canali, Franco Valzania, Elisabetta Sette, Maura Pugliatti, Valeria Tugnoli, Lucia Zinno, Salvatore Stano, Mario Santangelo, Silvia De Pasqua, Emilio Terlizzi, Donata Guidetti, Doriana Medici, Fabrizio Salvi, Rocco Liguori, Veria Vacchiano, Mario Casmiro, Pietro Querzani, Marco Currò Dossi, Alberto Patuelli, Simonetta Morresi, Marco Longoni, Patrizia De Massis, Rita Rinaldi, Annamaria Borghi, ERRALS GROUP, Amedeo Amedei, and Jessica Mandrioli
- Subjects
amyotrophic lateral sclerosis ,epidemiology ,population-based registry ,incidence ,clinical features ,genetics ,Biology (General) ,QH301-705.5 - Abstract
Increased incidence rates of amyotrophic lateral sclerosis (ALS) have been recently reported across various Western countries, although geographic and temporal variations in terms of incidence, clinical features and genetics are not fully elucidated. This study aimed to describe demographic, clinical feature and genotype–phenotype correlations of ALS cases over the last decade in the Emilia Romagna Region (ERR). From 2009 to 2019, our prospective population-based registry of ALS in the ERR of Northern Italy recorded 1613 patients receiving a diagnosis of ALS. The age- and sex-adjusted incidence rate was 3.13/100,000 population (M/F ratio: 1.21). The mean age at onset was 67.01 years; women, bulbar and respiratory phenotypes were associated with an older age, while C9orf72-mutated patients were generally younger. After peaking at 70–75 years, incidence rates, among women only, showed a bimodal distribution with a second slight increase after reaching 90 years of age. Familial cases comprised 12%, of which one quarter could be attributed to an ALS-related mutation. More than 70% of C9orf72-expanded patients had a family history of ALS/fronto-temporal dementia (FTD); 22.58% of patients with FTD at diagnosis had C9orf72 expansion (OR 6.34, p = 0.004). In addition to a high ALS incidence suggesting exhaustiveness of case ascertainment, this study highlights interesting phenotype–genotype correlations in the ALS population of ERR.
- Published
- 2022
- Full Text
- View/download PDF
28. Integrated Transcriptome Analysis of Human Visceral Adipocytes Unravels Dysregulated microRNA-Long Non-coding RNA-mRNA Networks in Obesity and Colorectal Cancer
- Author
-
Sabrina Tait, Antonella Baldassarre, Andrea Masotti, Enrica Calura, Paolo Martini, Rosaria Varì, Beatrice Scazzocchio, Sandra Gessani, and Manuela Del Cornò
- Subjects
obesity ,colorectal cancer ,adipocyte ,RNASeq ,microRNAs ,long non-coding RNAs ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Obesity, and the obesity-associated inflammation, represents a major risk factor for the development of chronic diseases, including colorectal cancer (CRC). Dysfunctional visceral adipose tissue (AT) is now recognized as key player in obesity-associated morbidities, although the biological processes underpinning the increased CRC risk in obese subjects are still a matter of debate. Recent findings have pointed to specific alterations in the expression pattern of non-coding RNAs (ncRNAs), such as microRNAs (miRNAs), and long non-coding RNAs (lncRNAs), as mechanisms underlying dysfunctional adipocyte phenotype in obesity. Nevertheless, the regulatory networks and interrelated processes relevant for adipocyte functions, that may contribute to a tumor-promoting microenvironment, are poorly known yet. To this end, based on RNA sequencing data, we identified lncRNAs and miRNAs, which are aberrantly expressed in visceral adipocytes from obese and CRC subjects, as compared to healthy lean control, and validated a panel of modulated ncRNAs by real-time qPCR. Furthermore, by combining the differentially expressed lncRNA and miRNA profiles with the transcriptome analysis dataset of adipocytes from lean and obese subjects affected or not by CRC, lncRNA–miRNA–mRNA adipocyte networks were defined for obese and CRC subjects. This analysis highlighted several ncRNAs modulation that are common to both obesity and CRC or unique of each disorder. Functional enrichment analysis of network-related mRNA targets, revealed dysregulated pathways associated with metabolic processes, lipid and energy metabolism, inflammation, and cancer. Moreover, adipocytes from obese subjects affected by CRC exhibited a higher complexity, in terms of number of genes, lncRNAs, miRNAs, and biological processes found to be dysregulated, providing evidence that the transcriptional and post-transcriptional program of adipocytes from CRC patients is deeply affected by obesity. Overall, this study adds further evidence for a central role of visceral adipocyte dysfunctions in the obesity–cancer relationship.
- Published
- 2020
- Full Text
- View/download PDF
29. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial)
- Author
-
Adriano Chiò, Christian Lunetta, Federico Casale, Letizia Mazzini, Andrea Calvo, Cristina Moglia, Jessica Mandrioli, Isabella Laura Simone, Giuseppe Fuda, Paolina Salamone, Giuseppe Marrali, Claudia Caponnetto, Vincenzo La Bella, Corrado Tarella, A Bombaci, M Brunetti, S Cammarosano, A Canosa, C Calvo, M Daviddi, G De Marco, P Cugnasco, M Grassano, B Iazzolino, A Ilardi, C Lauritano, A Lomartire, U Manera, L Solero, MC Torrieri; R Vasta, M Gilestro, VE Muccio; P Omedé, F Gerardi, C Cabona, G Novi, E Bersano, F De Marchi, R Spataro, R. Scimè, A Fasano, N Fini, A Gessani, E D’Errico, and A Scarafino
- Subjects
Medicine - Abstract
IntroductionAmyotrophic lateral sclerosis (ALS) is a fatal progressive neurological disorder characterised by a selective degeneration of motor neurons (MNs). Stem cell transplantation is considered as a promising strategy in neurological disorders therapy and the possibility of inducing bone marrow cells (BMCs) to circulate in the peripheral blood is suggested to investigate stem cells migration in degenerated ALS nerve tissues where potentially repair MN damage. Granulocyte-colony stimulating factor (G-CSF) is a growth factor which stimulates haematopoietic progenitor cells, mobilises BMCs into injured brain and it is itself a neurotrophic factor for MN. G-CSF safety in humans has been demonstrated and many observations suggest that it may affect neural cells. Therefore, we decided to use G-CSF to mobilise BMCs into the peripheral circulation in patients with ALS, planning a clinical trial to evaluate the effect of G-CSF administration in ALS patients compared with placebo.Methods and analysisSTEMALS-II is a phase II multicentre, randomised double-blind, placebo-controlled, parallel group clinical trial on G-CSF (filgrastim) and mannitol in ALS patients. Specifically, we investigate safety, tolerability and efficacy of four repeated courses of intravenous G-CSF and mannitol administered in 76 ALS patients in comparison with placebo (indistinguishable glucose solution 5%). We determine increase of G-CSF levels in serum and cerebrospinal fluid as CD34+ cells and leucocyte count after treatment; reduction in ALS Functional Rating Scale-Revised Score, forced vital capacity, Scale for Testing Muscle Strength Score and quality of life; the adverse events/reactions during the treatment; changes in neuroinflammation biomarkers before and after treatment.Ethics and disseminationThe study protocol was approved by the Ethics Committee of Azienda Ospedaliera Universitaria ‘Città della Salute e della Scienza’, Torino, Italy. Results will be presented during scientific symposia or published in scientific journals.Trial registration numberEudract 2014-002228-28.
- Published
- 2020
- Full Text
- View/download PDF
30. Editorial: Diet, Inflammation and Colorectal Cancer
- Author
-
Sandra Gessani, Fränzel J. Van Duijnhoven, and Maria Jesus Moreno-Aliaga
- Subjects
diet ,obesity ,inflammation ,colorectal cancer ,dietary factors ,Immunologic diseases. Allergy ,RC581-607 - Published
- 2019
- Full Text
- View/download PDF
31. Interplay between speech and gait variables in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation: A long‐term instrumental assessment
- Author
-
Cavallieri, Francesco, primary, Gessani, Annalisa, additional, Merlo, Andrea, additional, Campanini, Isabella, additional, Budriesi, Carla, additional, Fioravanti, Valentina, additional, Di Rauso, Giulia, additional, Feletti, Alberto, additional, Damiano, Benedetta, additional, Scaltriti, Sara, additional, Guagnano, Noemi, additional, Bardi, Elisa, additional, Corni, Maria Giulia, additional, Antonelli, Francesca, additional, Cavalleri, Francesca, additional, Molinari, Maria Angela, additional, Contardi, Sara, additional, Menozzi, Elisa, additional, Puzzolante, Annette, additional, Vannozzi, Giuseppe, additional, Bergamini, Elena, additional, Pavesi, Giacomo, additional, Fraix, Valérie, additional, Meoni, Sara, additional, Fraternali, Alessandro, additional, Versari, Annibale, additional, Lusuardi, Mirco, additional, Biagini, Giuseppe, additional, Pinto, Serge, additional, Moro, Elena, additional, and Valzania, Franco, additional
- Published
- 2023
- Full Text
- View/download PDF
32. Interplay between speech and gait variables in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation: A long‐term instrumental assessment
- Author
-
Francesco Cavallieri, Annalisa Gessani, Andrea Merlo, Isabella Campanini, Carla Budriesi, Valentina Fioravanti, Giulia Di Rauso, Alberto Feletti, Benedetta Damiano, Sara Scaltriti, Noemi Guagnano, Elisa Bardi, Maria Giulia Corni, Francesca Antonelli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Annette Puzzolante, Giuseppe Vannozzi, Elena Bergamini, Giacomo Pavesi, Valérie Fraix, Sara Meoni, Alessandro Fraternali, Annibale Versari, Mirco Lusuardi, Giuseppe Biagini, Serge Pinto, Elena Moro, and Franco Valzania
- Subjects
Neurology ,Neurology (clinical) - Published
- 2023
33. Insight into Elderly ALS Patients in the Emilia Romagna Region: Epidemiological and Clinical Features of Late-Onset ALS in a Prospective, Population-Based Study
- Author
-
Mandrioli, Giulia Gianferrari, Ilaria Martinelli, Cecilia Simonini, Elisabetta Zucchi, Nicola Fini, Maria Caputo, Andrea Ghezzi, Annalisa Gessani, Elena Canali, Mario Casmiro, Patrizia De Massis, Marco Curro’ Dossi, Silvia De Pasqua, Rocco Liguori, Marco Longoni, Doriana Medici, Simonetta Morresi, Alberto Patuelli, Maura Pugliatti, Mario Santangelo, Elisabetta Sette, Filippo Stragliati, Emilio Terlizzi, Veria Vacchiano, Lucia Zinno, Salvatore Ferro, Amedeo Amedei, Tommaso Filippini, Marco Vinceti, ERRALS GROUP ERRALS GROUP, and Jessica
- Subjects
amyotrophic lateral sclerosis ,elderly ALS ,epidemiology ,phenotype ,prognosis ,survival - Abstract
Few studies have focused on elderly (>80 years) amyotrophic lateral sclerosis (ALS) patients, who represent a fragile subgroup generally not included in clinical trials and often neglected because they are more difficult to diagnose and manage. We analyzed the clinical and genetic features of very late-onset ALS patients through a prospective, population-based study in the Emilia Romagna Region of Italy. From 2009 to 2019, 222 (13.76%) out of 1613 patients in incident cases were over 80 years old at diagnosis, with a female predominance (F:M = 1.18). Elderly ALS patients represented 12.02% of patients before 2015 and 15.91% from 2015 onwards (p = 0.024). This group presented with bulbar onset in 38.29% of cases and had worse clinical conditions at diagnosis compared to younger patients, with a lower average BMI (23.12 vs. 24.57 Kg/m2), a higher progression rate (1.43 vs. 0.95 points/month), and a shorter length of survival (a median of 20.77 vs. 36 months). For this subgroup, genetic analyses have seldom been carried out (25% vs. 39.11%) and are generally negative. Finally, elderly patients underwent less frequent nutritional- and respiratory-supporting procedures, and multidisciplinary teams were less involved at follow-up, except for specialist palliative care. The genotypic and phenotypic features of elderly ALS patients could help identify the different environmental and genetic risk factors that determine the age at which disease onset occurs. Since multidisciplinary management can improve a patient’s prognosis, it should be more extensively applied to this fragile group of patients.
- Published
- 2023
- Full Text
- View/download PDF
34. Deconstructing speech alterations in episodic ataxia type 2: Perceptual-acoustic analysis in a case due to CACNA1A gene mutation
- Author
-
Argenziano, Giacomo, primary, Cavallieri, Francesco, additional, Monfrini, Edoardo, additional, Gessani, Annalisa, additional, Russo, Marco, additional, Rizzi, Romana, additional, Fioravanti, Valentina, additional, Grisanti, Sara, additional, Toschi, Giulia, additional, Napoli, Manuela, additional, Pascarella, Rosario, additional, Budriesi, Carla, additional, Di Fonzo, Alessio, additional, Zucco, Riccardo, additional, and Valzania, Franco, additional
- Published
- 2023
- Full Text
- View/download PDF
35. Synthesis and Targeted Delivery of an Azidothymidine Homodinucleotide Conferring Protection to Macrophages against Retroviral Infection
- Author
-
Magnani, Mauro, Casabianca, Anna, Fraternale, Alessandra, Brandi, Giorgio, Gessani, Sandra, Williams, Rosamund, Giovine, Marco, Damonte, Gianluca, De Flora, Antonio, and Benatti, Umberto
- Published
- 1996
36. Epigenetic Modifications Induced by Nutrients in Early Life Phases: Gender Differences in Metabolic Alteration in Adulthood
- Author
-
Emanuela A. Greco, Andrea Lenzi, Silvia Migliaccio, and Sandra Gessani
- Subjects
epigenetics ,nutrition ,endocrine-disrupting chemicals ,development ,gender ,Genetics ,QH426-470 - Abstract
Metabolic chronic diseases, also named noncommunicable diseases (NCDs), are considered multifactorial pathologies, which are dramatically increased during the last decades. Noncommunicable diseases such as cardiovascular diseases, obesity, diabetes mellitus, cancers, and chronic respiratory diseases markedly increase morbidity, mortality, and socioeconomic costs. Moreover, NCDs induce several and complex clinical manifestations that lead to a gradual deterioration of health status and quality of life of affected individuals. Multiple factors are involved in the development and progression of these diseases such as sedentary behavior, smoking, pollution, and unhealthy diet. Indeed, nutrition has a pivotal role in maintaining health, and dietary imbalances represent major determinants favoring chronic diseases through metabolic homeostasis alterations. In particular, it appears that specific nutrients and adequate nutrition are important in all periods of life, but they are essential during specific times in early life such as prenatal and postnatal phases. Indeed, epidemiologic and experimental studies report the deleterious effects of an incorrect nutrition on health status several decades later in life. During the last decade, a growing interest on the possible role of epigenetic mechanisms as link between nutritional imbalances and NCDs development has been observed. Finally, because of the pivotal role of the hormones in fat, carbohydrate, and protein metabolism regulation throughout life, it is expected that any hormonal modification of these processes can imbalance metabolism and fat storage. Therefore, a particular interest to several chemicals able to act as endocrine disruptors has been recently developed. In this review, we will provide an overview and discuss the epigenetic role of some specific nutrients and chemicals in the modulation of physiological and pathological mechanisms.
- Published
- 2019
- Full Text
- View/download PDF
37. Transcriptome Profiles of Human Visceral Adipocytes in Obesity and Colorectal Cancer Unravel the Effects of Body Mass Index and Polyunsaturated Fatty Acids on Genes and Biological Processes Related to Tumorigenesis
- Author
-
Manuela Del Cornò, Antonella Baldassarre, Enrica Calura, Lucia Conti, Paolo Martini, Chiara Romualdi, Rosaria Varì, Beatrice Scazzocchio, Massimo D'Archivio, Andrea Masotti, and Sandra Gessani
- Subjects
obesity ,body mass index ,colorectal cancer ,adipocyte ,fatty acid ,transcriptome ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Obesity, a low-grade inflammatory condition, represents a major risk factor for the development of several pathologies including colorectal cancer (CRC). Although the adipose tissue inflammatory state is now recognized as a key player in obesity-associated morbidities, the underlying biological processes are complex and not yet precisely defined. To this end, we analyzed transcriptome profiles of human visceral adipocytes from lean and obese subjects affected or not by CRC by RNA sequencing (n = 6 subjects/category), and validated selected modulated genes by real-time qPCR. We report that obesity and CRC, conditions characterized by the common denominator of inflammation, promote changes in the transcriptional program of adipocytes mostly involving pathways and biological processes linked to extracellular matrix remodeling, and metabolism of pyruvate, lipids and glucose. Interestingly, although the transcriptome of adipocytes shows several alterations that are common to both disorders, some modifications are unique under obesity (e.g., pathways associated with inflammation) and CRC (e.g., TGFβ signaling and extracellular matrix remodeling) and are influenced by the body mass index (e.g., processes related to cell adhesion, angiogenesis, as well as metabolism). Indeed, cancer-induced transcriptional program is deeply affected by obesity, with adipocytes from obese individuals exhibiting a more complex response to the tumor. We also report that in vitro exposure of adipocytes to ω3 and ω6 polyunsaturated fatty acids (PUFA) endowed with either anti- or pro-inflammatory properties, respectively, modulates the expression of genes involved in processes potentially relevant to carcinogenesis, as assessed by real-time qPCR. All together our results suggest that genes involved in pyruvate, glucose and lipid metabolism, fibrosis and inflammation are central in the transcriptional reprogramming of adipocytes occurring in obese and CRC-affected individuals, as well as in their response to PUFA exposure. Moreover, our results indicate that the transcriptional program of adipocytes is strongly influenced by the BMI status in CRC subjects. The dysregulation of these interrelated processes relevant for adipocyte functions may contribute to create more favorable conditions to tumor establishment or favor tumor progression, thus linking obesity and colorectal cancer.
- Published
- 2019
- Full Text
- View/download PDF
38. Innate Lymphocytes in Adipose Tissue Homeostasis and Their Alterations in Obesity and Colorectal Cancer
- Author
-
Manuela Del Cornò, Lucia Conti, and Sandra Gessani
- Subjects
obesity ,colorectal cancer ,adipose tissue ,immune profile ,innate lymphocytes ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide and a leading cause of death, with burden expected to increase in the coming years. Enhanced adiposity, particularly visceral fat, is associated with increased cancer incidence representing an important indicator of survival, prognosis, recurrence rates, and response to therapy for several tumors including CRC. Compelling evidence has been achieved that the low-grade chronic inflammation characterizing obesity represents a main factor that can favor carcinogenesis. Adipocytes and adipose tissue (AT) infiltrating immune cells contribute to obesity-related inflammation by releasing soluble factors affecting, both locally and systemically, the function of several cell types, including immune and cancer cells. The unbalanced production of immune mediators as well as the profound changes in the repertoire and activation state of immune cells in AT of obese subjects represent key events in the processes that set the basis for a pro-tumorigenic microenvironment. AT harbors a unique profile of immune cells of different origin that play an important role in tissue homeostasis. Among these, tissue-resident innate lymphocytes are emerging as important AT components whose depletion/aberrant activation occurring in obesity could have an impact on inflammation and immune-surveillance against tumors. However, a direct link between obesity-induced dysfunction and cancer development has not been demonstrated yet. In this review, we provide an overview of human obesity- and CRC-induced alterations of blood and adipose tissue-associated innate lymphocytes, and discuss how the adipose tissue microenvironment in obesity might influence the development of CRC.
- Published
- 2018
- Full Text
- View/download PDF
39. Insight into Elderly ALS Patients in the Emilia Romagna Region: Epidemiological and Clinical Features of Late-Onset ALS in a Prospective, Population-Based Study
- Author
-
Gianferrari, Giulia, Martinelli, Ilaria, Simonini, Cecilia, Zucchi, Elisabetta, Fini, Nicola, Caputo, Maria, Ghezzi, Andrea, Gessani, Annalisa, Canali, Elena, Casmiro, Mario, De Massis, Patrizia, Curro' Dossi, Marco, De Pasqua, Silvia, Liguori, Rocco, Longoni, Marco, Medici, Doriana, Morresi, Simonetta, Patuelli, Alberto, Pugliatti, Maura, Santangelo, Mario, Sette, Elisabetta, Stragliati, Filippo, Terlizzi, Emilio, Vacchiano, Veria, Zinno, Lucia, Ferro, Salvatore, Amedei, Amedeo, Filippini, Tommaso, Vinceti, Marco, Errals Group, Null, and Mandrioli, Jessica
- Subjects
amyotrophic lateral sclerosis ,phenotype ,elderly ALS ,epidemiology ,prognosis ,survival - Published
- 2023
40. Interplay between speech and gait variables in PD patients treated with STN-DBS: A long-term instrumental assessment
- Author
-
Cavallieri, Francesco, Annalisa, Gessani, Merlo, Andrea, Campanini, Isabella, Budriesi, Carla, Fioravanti, Valentina, DI RAUSO, Giulia, Alberto, Feletti, Benedetta, Damiano, Scaltriti, Sara, Noemi, Guadagno, Bardi, Elisa, Corni, MARIA GIULIA, Antonelli, Francesca, Francesca, Cavalleri, Molinari, MARIA ANGELA, Sara, Contardi, Elisa, Menozzi, Puzzolante, Annette, Vannozzi, Giuseppe, Bergamini, Elena, Pavesi, Giacomo, Valérie, Fraix, Alessandro, Fraternali, Annibale, Versari, Lusuardi, Mirco, Biagini, Giuseppe, Serge, Pinto, Elena, Moro, and Valzania, Franco
- Subjects
Parkinson’s Disease ,STN-DBS ,speech ,Gait, deep brain stimulation, levodopa, Parkinson’s Disease, speech, STN-DBS ,levodopa ,Gait ,deep brain stimulation - Published
- 2023
41. Long-term effects of bilateral subthalamic nucleus deep brain stimulation on gait disorders in Parkinson’s disease: a clinical-instrumental study
- Author
-
Francesco Cavallieri, Isabella Campanini, Annalisa Gessani, Carla Budriesi, Valentina Fioravanti, Giulia Di Rauso, Alberto Feletti, Benedetta Damiano, Sara Scaltriti, Noemi Guagnano, Elisa Bardi, Maria Giulia Corni, Jessica Rossi, Francesca Antonelli, Francesca Cavalleri, Maria Angela Molinari, Sara Contardi, Elisa Menozzi, Annette Puzzolante, Giuseppe Vannozzi, Elena Bergamini, Giacomo Pavesi, Sara Meoni, Valérie Fraix, Alessandro Fraternali, Annibale Versari, Mirco Lusuardi, Giuseppe Biagini, Andrea Merlo, Elena Moro, and Franco Valzania
- Subjects
Neurology ,iTUG ,Deep brain stimulation, DBS, Gait, iTUG, Parkinson’s disease, Subthalamic nucleus ,Deep brain stimulation ,Parkinson’s disease ,DBS ,Neurology (clinical) ,Gait ,Subthalamic nucleus - Published
- 2023
42. Type I Interferons as Joint Regulators of Tumor Growth and Obesity
- Author
-
Sandra Gessani and Filippo Belardelli
- Subjects
type I interferons ,obesity ,cancer ,inflammation ,tumor microenvironment ,immunoregulation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Type I interferons (IFN-I) are antiviral cytokines endowed with multiple biological actions, including antitumor activity. Studies in mouse models and cancer patients support the concept that endogenous IFN-I play important roles in the control of tumor development and growth as well as in response to several chemotherapy/radiotherapy treatments. While IFN-I signatures in the tumor microenvironment are often considered as biomarkers for a good prognostic response to antitumor therapies, prolonged IFN-I signaling can lead to immune dysfunction, thereby promoting pathogen or tumor persistence, thus revealing the “Janus face” of these cytokines in cancer control, likely depending on timing, tissue microenvironment and cumulative levels of IFN-I signals. Likewise, IFN-I exhibit different and even opposite effects on obesity, a pathologic condition linked to cancer development and growth. As an example, evidence obtained in mouse models shows that localized expression of IFN-I in the adipose tissue results in inhibition of diet–induced obesity, while hyper-production of these cytokines by specialized cells such as plasmacytoid dendritic cells in the same tissue, can induce systemic inflammatory responses leading to obesity. Further studies in mouse models and humans should reveal the mechanisms by which IFN-I can regulate both tumor growth and obesity and to understand the role of factors such as genetic background, diet and microbioma in shaping the production and action of these cytokines under physiological and pathological conditions.
- Published
- 2021
- Full Text
- View/download PDF
43. HIV Exploitation of DC Biology to Subvertthe Host Immune Response
- Author
-
Del Cornò, Manuela, Conti, Lucia, Gauzzi, Maria Cristina, Fantuzzi, Laura, Gessani, Sandra, Gessani, Sandra, editor, and Belardelli, Filippo, editor
- Published
- 2007
- Full Text
- View/download PDF
44. Pearls & Oy-sters: Paroxysmal dysarthria-ataxia syndrome: Acoustic analysis in a case of antiphospholipid syndrome
- Author
-
Gessani, Annalisa, Cavallieri, Francesco, Budriesi, Carla, Zucchi, Elisabetta, Malagoli, Marcella, Contardi, Sara, Mascia, Maria Teresa, Giovannini, Giada, and Mandrioli, Jessica
- Published
- 2019
- Full Text
- View/download PDF
45. Highlights on the Role of Galectin-3 in Colorectal Cancer and the Preventive/Therapeutic Potential of Food-Derived Inhibitors
- Author
-
Aureli, Anna, primary, Del Cornò, Manuela, additional, Marziani, Beatrice, additional, Gessani, Sandra, additional, and Conti, Lucia, additional
- Published
- 2022
- Full Text
- View/download PDF
46. Added value of the instrumented Timed-Up and Go test (iTUG) in the long-term assessment of PD patients with bilateral subthalamic nucleus deep brain stimulation (STN-DBS)
- Author
-
Campanini, I., primary, Cavallieri, F., additional, Damiano, B., additional, Scaltriti, S., additional, Fioravanti, V., additional, Guagnano, N., additional, Vannozzi, G., additional, Bergamini, E., additional, Gessani, A., additional, Budriesi, C., additional, Antonelli, F., additional, Rispoli, V., additional, Lusuardi, M., additional, Valzania, F., additional, and Merlo, A., additional
- Published
- 2022
- Full Text
- View/download PDF
47. Bovine Lactoferrin-Induced CCL1 Expression Involves Distinct Receptors in Monocyte-Derived Dendritic Cells and Their Monocyte Precursors
- Author
-
Daniela Latorre, Nadia Pulvirenti, Daniela Angela Covino, Barbara Varano, Cristina Purificato, Gabriella Rainaldi, Maria Cristina Gauzzi, Laura Fantuzzi, Lucia Conti, Gloria Donninelli, Manuela Del Cornò, Michela Sabbatucci, Sandra Gessani, and Patrizia Puddu
- Subjects
monocyte ,dendritic cell ,lactoferrin ,CCL1 ,surface receptors ,Medicine - Abstract
Lactoferrin (LF) exhibits a wide range of immunomodulatory activities including modulation of cytokine and chemokine secretion. In this study, we demonstrate that bovine LF (bLF) up-modulates, in a concentration- and time-dependent manner, CCL1 secretion in monocytes (Mo) at the early stage of differentiation toward dendritic cells (DCs), and in fully differentiated immature Mo-derived DCs (MoDCs). In both cell types, up-modulation of CCL1 secretion is an early event following bLF-mediated enhanced accumulation of CCL1 transcripts. Notably, bLF-mediated up-regulation of CCL1 involves the engagement of distinct surface receptors in MoDCs and their Mo precursors. We show that bLF-mediated engagement of CD36 contributes to CCL1 induction in differentiating Mo. Conversely, toll-like receptor (TLR)2 blocking markedly reduces bLF-induced CCL1 production in MoDCs. These findings add further evidence for cell-specific differential responses elicited by bLF through the engagement of distinct TLRs and surface receptors. Furthermore, the different responses observed at early and late stages of Mo differentiation towards DCs may be relevant in mediating bLF effects in specific body districts, where these cell types may be differently represented in physiopathological conditions.
- Published
- 2015
- Full Text
- View/download PDF
48. Validation of the DYALS (dysphagia in amyotrophic lateral sclerosis) questionnaire for the evaluation of dysphagia in ALS patients
- Author
-
Diamanti, Luca, Borrelli, Paola, Dubbioso, Raffaele, Capasso, Margherita, Morelli, Claudia, Lunetta, Christian, Petrucci, Antonio, Mora, Gabriele, Volanti, Paolo, Inghilleri, Maurizio, Tremolizzo, Lucio, Mandrioli, Jessica, Mazzini, Letizia, Vedovello, Marcella, Siciliano, Gabriele, Filosto, Massimiliano, Matà, Sabrina, Montomoli, Cristina, DYALS Study Group (Giuliana Capece, Andrea, Ghezzi, Giuseppe, Fiamingo, Francesco Pio Ausiello, Laura, Ferri, Alberto, Doretti, Eleonora, Colombo, Gianluca, Demirtzidis, Vittorio, Riso, Federica, Bianchi, Micol, Castellari, Francesca, Madonia, Ceccanti, Marco, Cambieri, Chiara, Libonati, Laura, Fanella, Gaia, Carlo, Ferrarese, Annalisa, Gessani, Carla, Budriesi, Fabiola De Marchi, Francesca, Bianchi, Cecilia, Carlesi), Diamanti, Luca, Borrelli, Paola, Dubbioso, Raffaele, Capasso, Margherita, Morelli, Claudia, Lunetta, Christian, Petrucci, Antonio, Mora, Gabriele, Volanti, Paolo, Inghilleri, Maurizio, Tremolizzo, Lucio, Mandrioli, Jessica, Mazzini, Letizia, Vedovello, Marcella, Siciliano, Gabriele, Filosto, Massimiliano, Matà, Sabrina, Montomoli, Cristina, Diamanti, L, Borrelli, P, Dubbioso, R, Capasso, M, Morelli, C, Lunetta, C, Petrucci, A, Mora, G, Volanti, P, Inghilleri, M, Tremolizzo, L, Mandrioli, J, Mazzini, L, Vedovello, M, Siciliano, G, Filosto, M, Matà, S, and Montomoli, C
- Subjects
medicine.medical_specialty ,Multiple Sclerosis ,Neurology ,Dermatology ,Cronbach's alpha ,ALS ,Dysphagia ,Screening ,Humans ,Middle Aged ,Quality of Life ,Surveys and Questionnaires ,Amyotrophic Lateral Sclerosis ,Deglutition Disorders ,Internal medicine ,medicine ,Amyotrophic lateral sclerosis ,Neuroradiology ,business.industry ,Multiple sclerosis ,General Medicine ,medicine.disease ,Clinical trial ,Psychiatry and Mental health ,Neurology (clinical) ,Neurosurgery ,medicine.symptom ,business - Abstract
BACKGROUND: Dysphagia is a common symptom during the trajectory of ALS, and it can significantly impact on the quality of life and prognosis of patients. Nowadays, no specific tool for the screening of dysphagia in ALS is validated, and the approach is heterogeneous across the Italian centres. OBJECTIVE: To validate the DYALS (dysphagia in amyotrophic lateral sclerosis) questionnaire, adapting the DYMUS (dysphagia in multiple sclerosis) questionnaire, for the assessment of dysphagia in ALS patients, in order to uniform the evaluations across the Italian ALS network. METHODS: We included 197 patients diagnosed with ALS following the El Escorial criteria, in sixteen Italian ALS centres between 1st December 2019 and 1st July 2020. For each patient, we collected clinical and demographic data and obtained ALSFRS-r score, ALSAQ-5 score, DYMUS score, and EAT-10 score. RESULTS: Across the 197 patients, the ratio M/F was 113/84, and the median age was 64 years (IQR 56-72.5). Bulbar patients were 20%, and spinal patients 80%. The median ALSFRSr total score of patients was 35 (IQR 28-39). DYALS score was statistically higher in bulbar ALS than in spinal ALS (median = 6, IQR 4.5-9 vs median = 1, IQR 0-5, z = 6.253, p
- Published
- 2021
49. Shaping the Innate Immune Response by Dietary Glucans: Any Role in the Control of Cancer?
- Author
-
Manuela Del Cornò, Sandra Gessani, and Lucia Conti
- Subjects
innate immunity ,β-glucans ,nutrition ,immunotherapy ,cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
β-glucans represent a heterogeneous group of naturally occurring and biologically active polysaccharides found in many kinds of edible mushrooms, baker’s yeast, cereals and seaweeds, whose health-promoting effects have been known since ancient times. These compounds can be taken orally as food supplements or as part of daily diets, and are safe to use, nonimmunogenic and well tolerated. A main feature of β-glucans is their capacity to function as biological response modifiers, exerting regulatory effects on inflammation and shaping the effector functions of different innate and adaptive immunity cell populations. The potential to interfere with processes involved in the development or control of cancer makes β-glucans interesting candidates as adjuvants in antitumor therapies as well as in cancer prevention strategies. Here, the regulatory effects of dietary β-glucans on human innate immunity cells are reviewed and their potential role in cancer control is discussed.
- Published
- 2020
- Full Text
- View/download PDF
50. Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
- Author
-
Sandra Gessani and Filippo Belardelli
- Subjects
colorectal cancer ,dendritic cells ,immunotherapy ,pathogenesis ,risk factors ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Colorectal cancer (CRC), a multi-step malignancy showing increasing incidence in today’s societies, represents an important worldwide health issue. Exogenous factors, such as lifestyle, diet, nutrition, environment and microbiota, contribute to CRC pathogenesis, also influencing non neoplastic cells, including immune cells. Several immune dysfunctions were described in CRC patients at different disease stages. Many studies underline the role of microbiota, obesity-related inflammation, diet and host reactive cells, including dendritic cells (DC), in CRC pathogenesis. Here, we focused on DC, the main cells linking innate and adaptive anti-cancer immunity. Variations in the number and phenotype of circulating and tumor-infiltrating DC have been found in CRC patients and correlated with disease stages and progression. A critical review of DC-based clinical studies and of recent advances in cancer immunotherapy leads to consider new strategies for combining DC vaccination strategies with check-point inhibitors, thus opening perspectives for a more effective management of this neoplastic disease.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.